Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ePoster Display

413P - Butyrylcholinesterase as a predictive marker for wound infection in elective colorectal cancer surgery

Date

16 Sep 2021

Session

ePoster Display

Topics

Tumour Site

Colon and Rectal Cancer

Presenters

Francesk Mulita

Citation

Annals of Oncology (2021) 32 (suppl_5): S530-S582. 10.1016/annonc/annonc698

Authors

F. Mulita1, L. Tchabashvili2, E. Liolis3, M. Vailas2, K. Akinosoglou4, I. Maroulis2, G. Panos4

Author affiliations

  • 1 Department Of Surgery, University Hospital Patras, 265 00 - Patra/GR
  • 2 Department Of Surgery, University Hospital Patras, 26504 - Patra/GR
  • 3 Department Of Internal Medicine, Division Of Oncology, University Hospital Patras, 26504 - Patra/GR
  • 4 Department Of Internal Medicine And Infectious Diseases, University Hospital Patras, 26504 - Patra/GR

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 413P

Background

Surgical site infection (SSI) remains a frequent complication of elective colorectal cancer surgery. Butyrylcholinesterase (BChE), which is a cholinesterase enzyme synthesized in the liver, decreases in many clinical conditions such as liver damage, malnutrition, injury, and inflammation. The purpose of this study was to evaluate the efficacy of BChE as a tool for the diagnosis of SSI in elective operations for colorectal cancer.

Methods

Between June 2019 and March 2021, 196 consecutive patients who underwent elective colorectal cancer surgery were enrolled prospectively. Serum BChE concentrations were measured preoperatively and on postoperative (POD) days 1, 3, and 5. Group A included patients with SSI and Group B non-SSI patients. The normal range of BChE is roughly from 2800 U/L to 7400 U/L in our hospital laboratory. Statistical analyses were done using Stata13. Student’s t-test for normally distributed variables and Mann-Whitney U test for skewed variables were used to compare results between groups.

Results

SSI developed in 38 of the 196 patients (19.4%). Prior to surgery, there was no statistically significant difference in concentrations of BChE between the SSI and non-SSI groups (mean level of BChE for Group A=5490, Group B=5190; P=0.840). On POD 1 the mean level of BChE was 4680 in patients with wound infections, and 4670 in non-SSI patients (P=0.530). However, on POD 3 and 5 patients with SSI had significantly lower levels of serum BChE (mean level of BChE Group A=3920 vs Group B=4580; P<0.001, and Group A=4170 vs Group B=4770; P=0.002, respectively).

Conclusions

The current study demonstrates that BChE on POD 3 and 5 is a reliable marker for the presence of SSI in patients undergoing elective operations for colorectal cancer. According to the results of our study, serum BChE assessment could be included in routine clinical diagnostic procedures to evaluate patient postoperative infectious complications like SSI.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.